ABVX
Abivax S.A.
There isn't enough reported data to score ABVX yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ABVX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| Unavailable | |
| Unavailable |
There isn't enough reported data to rate ABVX's fundamentals.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ABVX PE Valuation
ABVX has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ABVX Forward outlook
There aren't enough analyst estimates for ABVX to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ABVX Earnings Per Share
ABVX and HIMS do not have enough comparable growth data to identify a winner.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ABVX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $2.6M | +3.5% |
| Q2 2023 | $2.5M | +0.9% |
| Q4 2018 | $358.8K | -8.2% |
| Q2 2018 | $546.6K | +12199% |
| Q4 2017 | $391K | +2414% |
| Q2 2017 | $4.4K | -97% |
| Q2 2016 | $152.2K | -56% |
ABVX's revenue has slid since its 2023 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2023 | -3975% | N/A |
| Q2 2023 | -1759% | N/A |
| Q4 2022 | -1726% | N/A |
| Q2 2022 | -836% | N/A |
| Q4 2018 | -3264% | +51157 points |
| Q2 2018 | -1741% | +6009 points |
| Q4 2017 | -1916% | N/A |
| Q2 2017 | -185150% | -182535 points |
ABVX's operating margin was −3975% last quarter, down 711 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ABVX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$57.9M | -$20.8M |
| Q4 2025 | -$79.2M | -$42.2M |
| Q2 2025 | -$37.1M | +$19.2M |
| Q4 2024 | -$37M | +$42.2M |
| Q2 2024 | -$56.3M | -$24.1M |
| Q4 2023 | -$79.2M | -$30.6M |
| Q2 2023 | -$32.2M | -$3.5M |
| Q4 2022 | -$48.6M | -$22.6M |
ABVX has burned cash in almost every quarter: −$211M over the past year, against −$216M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ABVX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +15% | +10.1M shares |
| 1 year | +27% | +16.7M shares |
| 3 years | +552% | +67.4M shares |
| 5 years | +725% | +70M shares |
| Available history | +759% | +70.4M shares |
ABVX has 80M diluted shares, up 27% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2025 | — |
| Q2 2025 | — |
| Q4 2024 | — |
| Q2 2024 | — |
| Q4 2023 | — |
| Q2 2023 | — |
| Q4 2022 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ABVX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ABVX Net Leverage
ABVX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ABVX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.0 | Neutral |
| Stochastic | 7.8 | Oversold |
ABVX's weekly RSI is 41 (neutral) and its Stochastic is 8 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ABVX PE vs Healthcare Sector
ABVX has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ABVX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $88.8 | 1.5% above |
| 20 week MA | $110.0 | 18% below |
| 50 week MA | $114.4 | 21% below |
| 100 week MA | $76.3 | 18% above |
ABVX has stronger trend alignment. ABVX is above 2 of 4 weekly averages versus HIMS above 0 of 5.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ABVX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $8.30 | $10.7 | +29% |
| 2024 | $10.7 | $7.12 | -33% |
| 2025 | $7.12 | $142.3 | +1899% |
| 2026 YTD | $142.3 | $90.2 | -37% |
ABVX has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.